Abstract 3181: A novel topoisomerase IIα 90 kDa isoform in etoposide resistant human leukemia K562 cells produced as a result of alternative RNA processing
Ragu Kanagasabai(University of Indianapolis), Jack C. Yalowich(University of Indianapolis), Lucas D. Serdar(Duke Medical Center), Corey A. Kientz(University of Indianapolis), Mary K. Ritke(University of Indianapolis), Terry S. Elton(The Ohio State University), Soumendrakrishna Karmahapatra(University of Indianapolis)
Cited by 0
Related Papers
COX-3, a cyclooxygenase-1 variant inhibited by acetaminophen and other analgesic/antipyretic drugs: Cloning, structure, and expression
|Proceedings of the National Academy of Sciences|2002|2k
ATP hydrolysis by UPF1 is required for efficient translation termination at premature stop codons
|Nature Communications|2016|63
hsa-miR-9-3p and hsa-miR-9-5p as Post-Transcriptional Modulators of DNA Topoisomerase IIα in Human Leukemia K562 Cells with Acquired Resistance to Etoposide
|Molecular Pharmacology|2019|23
Alternative RNA Processing of Topoisomerase IIα in Etoposide-Resistant Human Leukemia K562 Cells: Intron Retention Results in a Novel C-Terminal Truncated 90-kDa Isoform
|Journal of Pharmacology and Experimental Therapeutics|2016|21